Antipsychotic Polypharmacy and Metabolic Syndrome in Schizophrenia
Author Information
Author(s): Misawa Fuminari, Shimizu Keiko, Fujii Yasuo, Miyata Ryouji, Koshiishi Fumio, Kobayashi Mihoko, Shida Hirokazu, Oguchi Yoshiyo, Okumura Yasuyuki, Ito Hiroto, Kayama Mami, Kashima Haruo
Primary Institution: Yamanashi Prefectural KITA Hospital
Hypothesis
Is antipsychotic polypharmacy associated with metabolic syndrome even after adjustment for lifestyle effects?
Conclusion
Antipsychotic polypharmacy may be independently associated with an increased risk of having pre-metabolic syndrome.
Supporting Evidence
- 50.0% of patients were on antipsychotic polypharmacy.
- 22.2% of patients were in the metabolic syndrome group.
- Antipsychotic polypharmacy was significantly associated with the pre-metabolic syndrome group.
- Antipsychotic polypharmacy was not significantly associated with the metabolic syndrome group.
Takeaway
This study found that taking multiple antipsychotic medications might increase the risk of a health problem called pre-metabolic syndrome in people with schizophrenia.
Methodology
A cross-sectional survey was conducted with 334 patients to assess the association of metabolic syndrome with antipsychotic polypharmacy using multinomial logistic regression models.
Potential Biases
Potential bias due to high refusal rates and special conditions in antipsychotic treatment in Japan at the time of the study.
Limitations
The study had a cross-sectional design, moderate sample size, and did not assess other psychotropic drugs except antipsychotics.
Participant Demographics
Mean age was 44.2 years, with 42.8% female participants.
Statistical Information
P-Value
0.019
Confidence Interval
95% CI, 1.181-4.668
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website